Deep Track Capital, LP and David Kroin's Schedule 13G Filing for Enanta Pharmaceuticals, Inc.

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed a Schedule 13G with the SEC, disclosing their beneficial ownership of 1,484,513 shares of Enanta Pharmaceuticals, Inc.'s common stock, representing 5.33% of the outstanding shares as of October 9, 2025. The filing indicates that the shares are held for investment purposes and not for influencing the control of the issuer. The reporting persons have shared voting and dispositive power over the shares. The filing is made pursuant to Rule 13d-1(c) and includes a joint filing agreement among the reporting persons.